NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Norris SL, Lee NJ, Severance S, et al. Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report [Internet]. Portland (OR): Oregon Health & Science University; 2008 Aug.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus

Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report [Internet].

Show details

References

1.
CDC. National Diabetes fact sheet: general information and national estimates on diabetes in the United States. 2005.
2.
American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care. 2008;31( Suppl 1):S12–54. [PubMed: 18165335]
3.
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for Multiple Therapies (UKPDS 49) JAMA. 1999;281(21):2005–2012. [PubMed: 10359389]
4.
Anonymous. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews CRD report number 4. CRD. (2nd edition) 2001
5.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. American Journal of Preventive Medicine. 2001;20(3 Suppl):21–35. [PubMed: 11306229]
6.
Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. John Wiley & Sons, Inc; 2000.
7.
Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ. 2001 Jun 16;322(7300):1479–1480. [PMC free article: PMC1120528] [PubMed: 11408310]
8.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses . BMJ. 2003 Sep 6;327(7414):557–560. [PMC free article: PMC192859] [PubMed: 12958120]
9.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 Jun;21(11):1539–1558. [PubMed: 12111919]
10.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13;315(7109):629–634. [PMC free article: PMC2127453] [PubMed: 9310563]
11.
Review Manager (RevMan) [Computer program] Version 42 for Windows [computer program] Version. Oxford; England: The Cochrane Collaboration; 2002.
12.
R: A Language and Environment for Statistical Computing [computer program] Version. Vienna, Austria: R Foundation for Statistical Computing; 2006.
13.
Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 Oct;29(10):2189–2195. [PubMed: 17003291]
14.
Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.[see comment] Diabetes Care. 2002 Apr;25(4):724–730. [PubMed: 11919132]
15.
Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabetic Medicine. 2004 Nov;21(11):1204–1212. [PubMed: 15498087]
16.
Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003 Mar;26(3):784–790. [PubMed: 12610038]
17.
Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.[see comment] Diabetes Technology & Therapeutics. 2002;4(1):51–61. [PubMed: 12017421]
18.
Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007 Nov;30(11):2794–2799. [PubMed: 17698615]
19.
Marrero DG, Crean J, Zhang B, et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007 Feb;30(2):210–216. [PubMed: 17259483]
20.
Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. Journal of Clinical Endocrinology & Metabolism. 2007 Aug;92(8):2977–2983. [PubMed: 17504894]
21.
Karl D, Philis-Tsimikas A, Darsow T, et al. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technology & Therapeutics. 2007 Apr;9(2):191–199. [PubMed: 17425446]
22.
Ratner R, Whitehouse F, Fineman MS, et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Experimental & Clinical Endocrinology & Diabetes. 2005 Apr;113(4):199–204. [PubMed: 15891954]
23.
Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism: Clinical & Experimental. 2003 Dec;52(12):1638–1642. [PubMed: 14669170]
24.
Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obesity Research. 2004 Apr;12(4):661–668. [PubMed: 15090634]
25.
Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes, Obesity & Metabolism. 2003 Nov;5(6):408–414. [PubMed: 14617226]
26.
Davis S, Johns D, Maggs D, Northrup J, Xu H, Brodows R. Exploring the substitution of Exenatide for Insulin in patients with Type 2 Diabetes treated with insulin in combination with oral antidiabetic agents. Diabetes Care. 2007;30(11):2767–2772. [PubMed: 17595353]
27.
Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.[see comment][summary for patients in Ann Intern Med. 2005 Oct 18;143(8):I30; PMID: 16230718] Annals of Internal Medicine. 2005;143(8):559–569. [PubMed: 16230722]
28.
Nauck MADS, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007:259–267. [PubMed: 17160407]
29.
Secnik Boye K, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health & Quality of Life Outcomes. 2006;4:80. [PMC free article: PMC1634743] [PubMed: 17034640]
30.
Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clinical Therapeutics. 2007 Nov;29(11):2333–2348. [PubMed: 18158075]
31.
Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635. [PubMed: 15504997]
32.
DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in meformin-treated patients with type 2 diabetes . Diabetes Care. 2005;28(5):1092 – 1100. [PubMed: 15855572]
33.
Kendall D, Riddle M, Rosenstock J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a Sulfonylurea. Diabetes Care. 2005;28(5):1083–1091. [PubMed: 15855571]
34.
Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.[see comment][summary for patients in Ann Intern Med. 2007 Apr 3;146(7):I18; PMID: 17404346] Annals of Internal Medicine. 2007;146(7):477–485. [PubMed: 17404349]
35.
Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obesity & Metabolism. 2006 Jul;8(4):436–447. [PubMed: 16776751]
36.
Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clinical Therapeutics. 2007 Jan;29(1):139–153. [PubMed: 17379054]
37.
Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technology & Therapeutics. 2007;9(4):317–326. [PubMed: 17705687]
38.
Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism. 2006 July;8(4):419–428. [PubMed: 16776749]
39.
Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes/Metabolism Research Reviews. 2006 Nov–Dec;22(6):483–491. [PubMed: 16634116]
40.
King AB, Wolfe G, Healy S. Clinical observations of exenatide treatment. Diabetes Care. 2006;29(8):1984. [PubMed: 16873820]
41.
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007 Jul 11;298(2):194–206. [PubMed: 17622601]
42.
Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Current Medical Research & Opinion. 2007 Jul;23(7):1493–1507. [PubMed: 17559747]
43.
Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. Journal of Clinical Epidemiology. 1991;44(11):1271–1278. [PubMed: 1834807]
44.
Ahmad SR, Swann J. Exenatide and Rare Adverse Events. The New England Journal Of Medicine. 2008;358(18):1970–1971. [PubMed: 18456920]
45.
Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research & Opinion. 2008 Jan;24(1):275–286. [PubMed: 18053320]
46.
Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007 Jul;30(7):1862–1864. [PubMed: 17468348]
47.
Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes . Diabetes Care. 2006;29(12):2632–2637. [PubMed: 17130196]
48.
Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus . Diabetologia. 2006;49(11):2564–2571. [PubMed: 17001471]
49.
Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Research & Clinical Practice. 2008 Feb;79(2):291–298. [PubMed: 17933414]
50.
Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obesity & Metabolism. 2007;9(5):733–745. [PubMed: 17593236]
51.
Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, Obesity & Metabolism. 2008 [PubMed: 18201203]
52.
Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Current Medical Research & Opinion. 2008 Feb;24(2):537–550. [PubMed: 18194595]
53.
Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International Journal of Clinical Practice. 2007;61(1):171–180. [PubMed: 17156104]
54.
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J. Effect of intial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–1987. [PubMed: 17485570]
55.
Nauck Ma MG, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194–205. [PubMed: 17300595]
56.
Nonaka K KT, Sato A, Okuyama K, Fujimoto G, Hayashi N, Suzuki H, Hirayama Y, Stein P. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-IV (DPP-4) inhibitor, in Japanese patients with T2DM. Diabetes. 2007;9:194–205.
57.
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics. 2006;28(10):1556–1568. [PubMed: 17157112]
58.
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–2643. [PubMed: 17130197]
59.
Data on File. Supplemental dossier: Sitagliptin. Compiled October 2007.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK10608

Views

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...